Oral administration of osimertinib mesylate induced multiple peripheral neuropathy of a non-small-cell lung cancer patient and treated with traditional Chinese medicine - A case report.

ABSTRACT: Osimertinib mesylate (OM) is a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) for the targeted treatment of non-small-cell lung cancer (NSCLC). To date, some adverse effects of OM (such as rhabdomyolysis, severe rash, etc.) have been reported in clinic, but no cases of OM-induced multiple peripheral neuropathy (MPN) have been documented. Here we report a rare case about oral administration of OM-induced MPN in a NSCLC patient and its treatment with traditional Chinese medicine (TCM) decoction. After taking OM orally to treat NSCLC for 2 months, a 70-year-old man experienced MPN symptoms including numbness in hand and foot, weakness in both lower limbs, limited mobility, and eventually the loss of the ability to stand and walk. Meanwhile, other know

SUBMITTER: Huang X 

PROVIDER: S-EPMC12800394 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature